Plus Therapeutics Reveals Encouraging Update on GBM Trial
Plus Therapeutics Updates on ReSPECT-GBM Clinical Trial
Plus Therapeutics, Inc. (NASDAQ: PSTV), a company focused on creating targeted radiotherapeutics for central nervous system cancers, recently provided an update on their ongoing ReSPECT-GBM Phase 1/2 clinical trial. This trial evaluates the effectiveness of Rhenium (186Re) Obisbemeda for treating recurrent glioblastoma, a particularly aggressive form of brain cancer.
Safety and Efficacy Observations
The trial has yielded promising data, consistently demonstrating safety and potential efficacy. Among the 42 patients enrolled across three sites, most have shown a positive response to the treatment with only one notable dose-limiting toxicity reported. This reflects a favorable safety profile amidst the challenging landscape of glioblastoma treatment options.
Trial Details and Current Patient Enrollment
As of the latest update, 19 out of the 42 participants have received treatment at the recommended Phase 2 dosage, which is set at 22.3 mCi infused into small to medium-sized tumor volumes. The average tumor size treated in this trial is 7.5 mL, highlighting an effective method of targeting the administration of Rhenium (186Re) Obisbemeda.
Encouraging Trends in Absorbed Dose
Analysis indicates that 89% of the Phase 2 participants exceeded the minimum dose threshold required for efficacy, achieving an average absorbed radiation dose of 300 Gy. Notably, this increase in absorbed dose correlates with enhanced delivery parameters, such as infusion rate and number of catheters used, underscoring the importance of precise delivery in optimizing treatment outcomes.
Key Highlights from the Trial
A summary of critical findings from the ReSPECT-GBM trial update emphasizes:
- A total of 42 patients have been enrolled, with 19 patients treated at the recommended doses.
- All participants have had recurrent glioblastoma, which has been confirmed histologically.
- Average radiation treatment reached 300 Gy, and a significant portion of patients achieved important drug delivery parameters correlating with survival.
- In Phase 2, most adverse events reported were mild to moderate, suggesting manageable safety concerns.
- A statistically significant tumor volume reduction was observed in patients receiving greater than 100 Gy absorbed doses.
Next Steps for Plus Therapeutics
Marc H. Hedrick, M.D., President and CEO of Plus Therapeutics, shared optimism regarding the trial's progress. The announcement of new clinical trial sites, especially in notable academic institutions, aims to accelerate patient enrollment in both the Phase 1 and Phase 2 arms of the trial.
About Glioblastoma (GBM)
Glioblastoma is a devastating cancer affecting approximately 15,000 individuals in the U.S. each year. Despite ongoing research, survival rates remain low, with most patients facing recurrence shortly after treatment. Currently, effective therapies to extend patient survival are significantly limited.
Innovative Approach with Rhenium (186Re) Obisbemeda
Rhenium (186Re) Obisbemeda represents a novel injectable radiotherapy designed to deliver targeted high-dose radiation directly to tumors. Its unique formulation aims to improve safety and efficacy compared to existing therapies, making it a hopeful option in challenging treatment scenarios like recurrent glioblastoma.
Convection Enhanced Delivery (CED): A Revolutionary Method
CED is a groundbreaking approach facilitating the targeted distribution of drugs to the brain, which involves strategic catheter placements in the tumor. This technique is pivotal in ensuring that therapeutic doses reach affected areas effectively.
Frequently Asked Questions
What is the focus of the ReSPECT-GBM trial?
The ReSPECT-GBM trial evaluates Rhenium (186Re) Obisbemeda for its safety and efficacy in treating recurrent glioblastoma.
How many patients are currently enrolled in the trial?
A total of 42 patients have been enrolled across three clinical trial sites.
What are the recent findings from the trial?
Recent updates indicate that 89% of Phase 2 patients received sufficient doses, showing a favorable safety profile.
Why is Rhenium (186Re) Obisbemeda important?
This treatment is a novel approach that potentially offers higher targeted radiation doses directly to tumors, which may improve outcomes for patients with limited options.
How is Plus Therapeutics advancing this research?
Plus Therapeutics is actively enrolling patients in the trial and expanding their research sites to enhance the pace and reach of the study.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- RIFM to Host 3rd Annual Science Symposium Focusing on Safety
- DA Davidson's Positive Outlook on Datadog's Growth Potential
- LiTime Offers Massive Discounts on Energy Storage Solutions
- Global Pet Supplement Market to Exceed $1 Billion by 2035
- Metallurgical Coal Market Forecast: Surplus Ahead by 2025
- Maria Lensing Steps Up as CTO of Sorenson to Drive Innovation
- AE Industrial Partners Welcomes Leonard Dollaga as Managing Director
- New Developments and Growth Potential for Gain Therapeutics
- Wiley's Expansion of Advanced Journal Portfolio Unveiled
- AEON Biopharma Sees Positive Updates Heading into 2025
Recent Articles
- Top Warren Buffett Stocks to Watch in 2024 and Beyond
- Abeona Therapeutics Expands Team with Inducement Grants for New Hires
- Intellia Therapeutics Showcases Exciting Advances in Gene Therapy
- Boeing Explores $10 Billion Equity Offering Amidst Challenges
- Safe Harbor Financial Set to Shine at Benzinga Cannabis Event
- VR Resources Reports Promising Copper and Silver Grades
- Top 3 Stock Picks for October 2024: How to Invest Smartly
- Understanding Brent Oil: Traders Shift U.S. Shipments Raising Concerns
- Cartier Resources Boosts Gold Exploration with New Drill Rig
- Drive-Thru Satisfaction: Insights from the 2024 Study
- Cognition Therapeutics Champions Awareness for Lewy Body Dementia
- Watsco Announces $2.70 Quarterly Dividend for Shareholders
- Transform Your Home Entertainment with Stingray Karaoke App
- Altimmune Set to Share Insights at Major Virtual Conference
- John Brace Steps in as Interim CEO of Northland Power Inc.
- Ranpak Achieves Triple Honors at 2024 Packaging Gateway Awards
- RevitaLash Cosmetics Surpasses $9 Million Against Breast Cancer
- Marex Expands Environmental Solutions with Dropet Acquisition
- Costamare Inc. Announces Latest Dividends for Investors
- Electra Battery Materials Welcomes New Construction Director
- Borr Drilling Limited Q3 2024: Webcast and Conference Call Details
- Apollo's Vision for Growth: Investor Day Insights Unveiled
- ReCode Therapeutics Expands Scientific Team for mRNA Advances
- Celebrating Literary Excellence in the Readers' Favorite Awards
- The Ripple Effect of the Weak Dollar on Bitcoin's Future
- Threema Recognized as Leader in Secure Messaging Solutions
- Cybin's Strategic Team Expansion for Phase 3 Trial Success
- Renovus Capital Partners Finalizes LeapPoint Sale to Omnicom
- Celebrating Excellence in Medical Education: 2025 ACGME Winners
- Cencora Set to Release Fourth Quarter Fiscal 2024 Earnings
- Palatin Technologies Shares Key Updates and Year-End Financials
- ZenaTech Inc. Takes Flight with Direct Nasdaq Listing ZENA
- Arcos Dorados Expands Future Growth Through Franchise Renewal
- Chinese EV Leaders Nio, XPeng, and Li Auto: A Market Surge
- Leadership Transition at Convergix Automation Solutions
- Delek Logistics Expands Operations with New 12-Year Agreement
- XTM's 2023 Financial Results: Growth and Future Plans
- Conagra Brands Declares New Quarterly Dividend for Shareholders
- Welltower Inc. Enhances Healthcare Infrastructure and Services
- GlobalMindED Hosts Event to Strengthen Diverse Talent Growth
- Dunhill Homes Announces Exciting Return with New Developments
- RIV Capital Welcomes David E. Vautrin as New Interim CEO
- Hamilton Zanze Secures Successful Sale of Maple Bay Townhomes
- Kevin Jennings Joins Scottie Resources as Strategic Advisor
- Annovis Bio's Innovative Approach to Neurodegenerative Diseases
- Russel Metals Announces Redemption of 5.75% Senior Notes
- Citi Adjusts Fluence Energy's Outlook: A Neutral Perspective
- Callan Welcomes Francis Griffin as Senior Consultant in Credit
- Peraso Inc. Targets Growth with New Orders Despite Challenges
- QuickLogic Achieves Milestone with Custom eFPGA IP Delivery